Figure 2.
The spatial expression of CXCL4 marks the progression of BM fibrosis in patients. (A) Representative images of CXCL4 grading (1-4) in human BM biopsy samples. Original magnification ×20. Scale bar, 50 μm. (B) Description of the main features of CXCL4 grading scale in human BM biopsy samples. (C) Quantification of the CXCL4 grade in MPN and controls. Data shown as median; Mann-Whitney U test. (D) Quantification of the CXCL4 grade compared with myelofibrosis grade (reticulin staining). Kruskal-Wallis test followed by Dunn’s post hoc test. (E) Comparison of hemoglobin levels vs CXCL4 grade. (F) Comparison of WBCs vs CXCL4 grade. Controls, n = 8; MPN, n = 40. Patient characteristics are shown in supplemental Tables 1 and 2. **P < .01, ****P < .0001.

The spatial expression of CXCL4 marks the progression of BM fibrosis in patients. (A) Representative images of CXCL4 grading (1-4) in human BM biopsy samples. Original magnification ×20. Scale bar, 50 μm. (B) Description of the main features of CXCL4 grading scale in human BM biopsy samples. (C) Quantification of the CXCL4 grade in MPN and controls. Data shown as median; Mann-Whitney U test. (D) Quantification of the CXCL4 grade compared with myelofibrosis grade (reticulin staining). Kruskal-Wallis test followed by Dunn’s post hoc test. (E) Comparison of hemoglobin levels vs CXCL4 grade. (F) Comparison of WBCs vs CXCL4 grade. Controls, n = 8; MPN, n = 40. Patient characteristics are shown in supplemental Tables 1 and 2. **P < .01, ****P < .0001.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal